Advances towards the design and development of personalized non-small-cell lung cancer drug therapy.

about

Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer

P2860

Q36022297-E876601E-0953-4FA3-A249-108F8A236CCC

P2860

Advances towards the design and development of personalized non-small-cell lung cancer drug therapy.

Item

http://www.wikidata.org/entity/Q38148583

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Advances towards the design an ...... cell lung cancer drug therapy.

@en

type

Item

label

Advances towards the design an ...... cell lung cancer drug therapy.

@en

prefLabel

Advances towards the design an ...... cell lung cancer drug therapy.

@en

P1476

Advances towards the design an ...... -cell lung cancer drug therapy

@en

P2093

Alain Gelibter

http://www.w3.org/2001/XMLSchema#string

Anna Ceribelli

http://www.w3.org/2001/XMLSchema#string

Francesco Cognetti

http://www.w3.org/2001/XMLSchema#string

Michele Milella

http://www.w3.org/2001/XMLSchema#string

Ruggero De Maria

http://www.w3.org/2001/XMLSchema#string

Sabrina Vari

http://www.w3.org/2001/XMLSchema#string

Ursula Cesta Incani

http://www.w3.org/2001/XMLSchema#string

P2860

First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting

Global cancer statistics

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling

Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models

Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas

The genetic basis for cancer treatment decisions

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

P304

1381-1397

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/17460441.2013.843523

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-10-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257309226

http://www.w3.org/2001/XMLSchema#string

P698

24088065

http://www.w3.org/2001/XMLSchema#string

Advances towards the design and development of personalized non-small-cell lung cancer drug therapy.

about

P2860

P2860

Advances towards the design and development of personalized non-small-cell lung cancer drug therapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698